NCT05128773View on ClinicalTrials.gov

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

PHASE3TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

October 13, 2022

Study Completion Date

October 13, 2022

Conditions
Breast Cancer
Interventions
DRUG

Amcenestrant

tablet, oral

DRUG

Tamoxifen

tablet, oral

DRUG

Amcenestrant-matching placebo

tablet, oral

DRUG

Tamoxifen-matching placebo

tablet, oral

Trial Locations (2)

570311

Investigational Site Number :1561599, Haikou

Unknown

Investigational Site Number :1521622, Santiago

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Breast International Group

OTHER

collaborator

Alliance Foundation Trials, LLC.

OTHER

collaborator

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

lead

Sanofi

INDUSTRY